Ankylosing spondylitis is a chronic inflammatory disease that mainly affects the sacroiliac joints and the spine, and in severe cases can cause spinal ankylosis and affect the quality of life of patients. The etiology is unclear, it is common in young adults, and it is difficult to treat. Early diagnosis and early treatment are key to improving the prognosis. Exercise has a therapeutic effect and is essential throughout the treatment process and in maintaining remission. I. Intensive treatment (to achieve the above-mentioned goals in the shortest possible time) 1. Hormones: prednisone, Depo-Provera, methylprednisolone, etc. Features: can quickly eliminate inflammation and analgesia, significantly improve symptoms, increase spinal mobility in the short term, slow down the pace of disability and improve the patient’s quality of life. Inexpensive but to bear more side effects of drugs, as a bridge treatment is a good means of high-dose intensive small-dose maintenance, early discontinuation of drugs. 2, biological agents: Ixepro, prednisone, Enzyme, classical gram, Xiomel and Yamiro, etc. Features: rapid relief, small side effects, is the best choice in the current treatment, but more expensive, some patients may be ineffective, if economic conditions allow, can be applied for a long time. Second, maintenance therapy (to maintain long-term clinical remission after the treatment has reached the standard) 1, functional exercise: is an important part of the treatment process. 2.Non-steroidal anti-inflammatory drugs: meloxicam, lexon, vinpocetine, ciloxib, etoricoxib, etc. Features: It is a basic drug, with anti-inflammatory and analgesic effect, inhibiting the formation of bone redundancy and delaying the effect of ankylosis, the main side effects are gastrointestinal reactions, if there is no special can be used for a long time. 3.Biotics: Ixep, prednisolone, enzyme, classical gram, Xumel and Yamiro, etc. Features: rapid relief, small side effects, long-term application, if economic conditions allow is currently the best choice in maintenance treatment, such as a biological agent is not effective can be converted to another, still effective, but to closely follow up to exclude infection and other diseases. 4, DMARDs: for remission drugs, the main drugs are methotrexate, leflunomide, cyclophosphamide, mycophenolate, azathioprine, salazosulfapyridine and hydroxychloroquine sulfate, elamodex, tacrolimus, etc. Features: Used for patients with peripheral joint and extra-articular manifestations, to be applied in combination with cycles for a long time, the dosage can be increased or decreased in steps according to the condition and immune function status, and most patients can stop the drug, but long-term follow-up observation is required.